Generated by AI
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Alzamend Neuro’s current pipeline centers on AL001, a patented ionic cocrystal formulation that combines lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine candidate designed to help restore the immune system’s ability to combat Alzheimer’s disease. The company is working across major therapeutic areas including Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its research and development activities are directed toward advancing novel product candidates intended to address conditions with significant unmet medical need in neuroscience and mental health. Headquartered in Atlanta, Georgia, Alzamend Neuro plays a specialized role in the biotech market as a developer of investigational therapies focused on the central nervous system and immune-based approaches to Alzheimer’s disease.
Website3480 Peachtree Road NE
Atlanta, GA, 30326
United States
The latest articles about ALZN.
Alzamend Neuro (ALZN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Centene (CNC) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Summary of Aug 11's posts. Generated by AI.
Summary of Aug 5's posts. Generated by AI.
Summary of Feb 19's posts. Generated by AI.
Summary of Aug 11's posts. Generated by AI.
Investors talking about ALZN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.